{"id":"NCT01000974","sponsor":"GlaxoSmithKline","briefTitle":"Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants","officialTitle":"Phase III, Partially Double-blind Study to Evaluate Consistency and Immunogenicity of 3 Lots of GSK Biologicals' Hib Conjugate Vaccine 208108 Versus ActHIB and Pentacel at 2, 4, 6 and 15-18 Months of Age in Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06-18","primaryCompletion":"2011-11-18","completion":"2013-07-17","firstPosted":"2009-10-23","resultsPosted":"2013-08-19","lastUpdate":"2018-07-12"},"enrollment":4003,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Haemophilus Influenzae Type b"],"interventions":[{"type":"BIOLOGICAL","name":"GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)","otherNames":["Hiberix®"]},{"type":"BIOLOGICAL","name":"ActHIB™","otherNames":[]},{"type":"BIOLOGICAL","name":"Pentacel™","otherNames":[]},{"type":"BIOLOGICAL","name":"Pediarix™","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevnar 13™","otherNames":[]},{"type":"BIOLOGICAL","name":"Rotarix™","otherNames":[]},{"type":"BIOLOGICAL","name":"Engerix™-B","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix™","otherNames":[]}],"arms":[{"label":"Hiberix Group","type":"EXPERIMENTAL"},{"label":"ActHIB Group","type":"ACTIVE_COMPARATOR"},{"label":"Pentacel Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate safety, to demonstrate lot-to-lot consistency of the vaccine, to address the relevant concomitant vaccine administrations and to provide a comparison between GSK Biologicals' Hib conjugate vaccine and the licensed monovalent Hib vaccine ActHIB as well as the licensed combination product Pentacel in infants at 2, 4, 6 and 15-18 months of age. This study is designed with a primary and a booster phase.","primaryOutcome":{"measure":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0 µg/mL","timeFrame":"At 1 month after last dose of primary vaccination","effectByArm":[{"arm":"Hiberix Group","deltaMin":1536,"sd":null},{"arm":"ActHIB Group","deltaMin":265,"sd":null},{"arm":"Pentacel Group","deltaMin":234,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":63,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":120,"n":2963},"commonTop":["Irritability","Somnolence","Pain","Decreased appetite","Erythema"]}}